AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01706952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
Study NCT01706952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
Study NCT01706952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
Study NCT03430037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Flavonoid Family
Study NCT03430037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT04469465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet
Study NCT04469465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT04469465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C5 Inhibitor
Description: Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
Study NCT04469465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C5 Inhibitor
Description: Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
Study NCT02717949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/ledipasvir
Description: sofosbuvir ledipasvir fixed dose combination given once a day by mouth
Study NCT02717949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
Study NCT02717949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin 1200 mg given orally in divided dose for those >75kg and 1000 mg in divided dose for those \<75 kg.
Study NCT03036566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithium disilicate ceramic (Ivoclar)
Description: Three unit high strength ceramic bridges replacing a single tooth.
Study NCT00913159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Description: Using electric shock wave to treat urolithiasis
Study NCT04527159 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoraphat Pro / VivaSens
Description: desensitizing agents for treatment of dentinal hypersensitivity
Study NCT01814917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
Study NCT01814917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBPB
Study NCT04170569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
Study NCT03130777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Description: The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
Study NCT03683719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.
Study NCT03950024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional brain MRI
Description: The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
Study NCT03950024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional brain MRI
Description: The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
Study NCT03738904 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
Study NCT03738904 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Oxcodone PO Ketorolac IV only (intraop)
Study NCT01587326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: escitalopram 10 mg/d to 20 mg/d
Study NCT03708341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Systematic daily administration of melatonin 5 mg during patient's ICU stay
Study NCT03708341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Systematic daily administration of placebo during patient's ICU stay
Study NCT01316848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
Study NCT03683719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT03260816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Parent-Child Interaction Therapy (I-PCIT)
Description: Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
Study NCT03260816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referrals as Usual (RAU)
Description: Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
Study NCT03140527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study NCT03637751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Trier Social Stress Test
Study NCT03637751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
Study NCT02473575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine gum
Description: Gum is consumed 30 minutes before commencement of run
Study NCT02473575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gum
Description: Gum is consumed 30 minutes before commencement of run
Study NCT00515333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule; 60 milligrams; t.i.d.
Study NCT00515333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule; 30 milligrams; t.i.d.
Study NCT00515333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard capsule; 0 milligrams; t.i.d.
Study NCT00515333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule, 100 milligrams, t.i.d.
Study NCT02123407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticles
Description: Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
Study NCT02123407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with D2 dissection
Description: In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
Study NCT01648777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L bupivacaine
Description: L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
Study NCT01648777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
Study NCT00453765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast, 8 weeks, once daily, 10 milligrams
Study NCT00453765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02385955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative double unit cord blood transplantation
Description: Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
Study NCT01792999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced KBCT
Description: Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
Study NCT01782677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Surgical Resection of Carotid Bodies
Study NCT02126254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic group
Description: NICAS guided treatment
Study NCT03140527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02665481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Study NCT02665481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02665481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study NCT03140527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active
Study NCT01351194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
Study NCT01351194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
Study NCT02479425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient positioning
Description: positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
Study NCT02479425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient positioning
Description: positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
Study NCT03977324 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03977324 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03977324 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective Tissue Graft
Description: CTG will be positioned in the buccal aspect of the peri-implant tissue
Study NCT03488381 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soccer Heading
Description: Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals.
Study NCT03488381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soccer Heading
Description: Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals.
Study NCT00388518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: 45mg po daily
Study NCT00388518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study NCT00388518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
Study NCT04600648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum insulin level
Description: Measure levels before and after weight loss related to bariatric surgery
Study NCT04600648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Leptin test
Description: Measure levels before and after weight loss related to lifestyle change weight loss
Study NCT01478698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA 10mg per dose intraperitoneal
Study NCT03530007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: normal saline used for prevention of spinal shivering
Study NCT01478698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant deoxyribonuclease (DNase)
Description: DNase 5mg per dose given intraperitoneally.
Study NCT00466193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate sublingual tablet
Description: 3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study NCT00466193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study NCT03530007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: ondansetron 4 MG used for prevention of spinal shivering
Study NCT02304042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin will be given slowly iv after delivery of the anterior shoulder.
Study NCT02304042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given slowly iv after delivery of the anterior shoulder.
Study NCT01375049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation Solution (AZLI)
Description: AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
Study NCT04065724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical training as resistance and aerobic training.
Study NCT03394391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily ART-adherence SMS reminder
Description: Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
Study NCT03394391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Adherence Counselling/Patient experience group chat
Description: All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.
Study NCT03394391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Adherence Counselling/Patient experience group chat
Description: All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.
Study NCT03530007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: ondansetron 8 MG used for prevention of spinal shivering
Study NCT02563158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-occlusion technique
Description: Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
Study NCT01383902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Food type
Description: 1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
Study NCT01363778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
Study NCT01484470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StemEx
Description: For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up.
Study NCT03056703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One Fast Release Tablet containing 1000 mg acetylsalicylic acid
Study NCT03056703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
Study NCT03004534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darolutamide
Description: Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
Study NCT03311074 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Strimvelis
Description: Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
Study NCT01086553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 9mg budesonide OD